• Founded: 2021
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Norovirus (adult)
  • Drug types: INF, VAC, PED, GER
  • Lead product: HIL-214
  • Product link: https://www.hillevax.com/pipeline/
  • Funding: $200M IPO Apr 2022; $135M Sep 2021



job board

Short description:

Norovirus Vaccine

Drug notes:

Also 3 additional trials Clin2 norovirus (infants, children, older adults)

Long description:

HilleVax is focused on developing vaccines against Norovirus. Norovirus is the most common viral cause of acute gastroenteritis worldwide and causes 200,000 deaths annually. It can cause illness at any age, but young children and older adults are at most risk. To prevent illness from infection, HilleVax is assembling experience in vaccine development, clinical trial operations, manufacturing and commercialization. HilleVax’s current lead product vaccine is HIL-214, a bivalent virus-like particle vaccine for active immunization against norovirus. HIL-214 is in clinical trials for all age-groups from infants to older adults, with current data showing the vaccine to be well tolerated and clinical proof of concept in preventing acute gastroenteritis.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com